Based on this robust clinical evidence, the National Comprehensive Cancer Network Clinical Practice Guidelines have recommended the ribociclib adjuvant treatment regimen as a Category 1 preferred treatment option for patients with high-risk HR+/HER2- early breast cancer, thereby establishing its standard position in the comprehensive management of breast cancer throughout the disease course. The gene discussed is ERBB2; the disease is breast cancer.